4,901 trials
Carcinoma, Non-Small-Cell Lung · Lung Neoplasms
Primary: Part A, Cmax: Geometric Mean Maximum Observed Plasma Concentration (Cmax) for Midazolam Administered Orally With Mobocertinib (Cycle 1 Day 24) and Without Mobocertinib…
Septic Shock
Primary: Standing Dose of Norepinephrine Which is Required to Maintain a Mean Arterial Pressure (MAP) of 65 mmHg - Hour 1 — 7.4; 27.6 mcg/min
Metastatic Castration-resistant Prostate Cancer
Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 14; 15; 13; 7 Participants
Rabies · Rabies Immunisation
Primary: Number and Percentage of Participants With Solicited Injection Site Reactogenicity Events in Each Treatment Arm and Overall — 3; 2; 0; 0 Participants
Healthy
Primary: Area Under the Plasma-Concentration Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of PF-07104091 for Treatment A, B, and C — 10920; 10720; 11200…
Malignant Glioma · Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma
Primary: Percentage of Participants With Unacceptable Toxicity — 0 percentage of participants
Acute Lymphoblastic Leukemia
Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 0 Participants
Hyperkalaemia
Primary: Maximum Observed Concentration (Cmax) — 27140; 19350; 593.6; 608.1 Picogram/milliliter (pg/ml)
Advanced Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Hiv · HIV Infections · AIDS
Primary: Safety (Adverse Event Rate) — 20 adverse events per participant
Ovarian Cancer
Primary: Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) in Safety Run-in (Part 1) — 0; 0 percentage of participants
Healthy Participants
Primary: Plasma Dabigatran (Total) PK Parameters (PF-07321332/Ritonavir Co-administered With Dabigatran [Treatment 2]): Maximum Plasma Concentration (Cmax) — 71.87; 154.1 ng/mL
Healthy
Primary: Total Recovery of Radioactivity in Urine, Expressed as Percentage of Total Radioactive Dose Administered — 13.98 Percentage of total radioactive dose
Healthy Volunteers
Primary: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan — 228; 216; 219 ng•h/mL
Inflammatory Diseases
Primary: Maximum Observed Serum Concentration (Cmax) of Efavaleukin Alfa — 26.9; 41.6; 48.1; 56.1 ng/mL